ProSavin is an experimental drug believed to be of use in the treatment of Parkinson's disease. It is administered to the striatum in the brain, inducing production of dopamine. [1]
It is manufactured by Oxford BioMedica. Results from a Phase I/II clinical trial were published in the Lancet [2] and showed safety, but little efficacy. [3] ProSavin was superseded by AXO-Lenti-PD (OXB-102), an optimized version of the drug. [4]
Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase, tyrosine hydroxylase and GTP-cyclohydrolase 1, to the striatum in the brain, reprogramming transduced cells to secrete dopamine. [5] [6]
ProSavin is an experimental drug believed to be of use in the treatment of Parkinson's disease. It is administered to the striatum in the brain, inducing production of dopamine. [1]
It is manufactured by Oxford BioMedica. Results from a Phase I/II clinical trial were published in the Lancet [2] and showed safety, but little efficacy. [3] ProSavin was superseded by AXO-Lenti-PD (OXB-102), an optimized version of the drug. [4]
Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase, tyrosine hydroxylase and GTP-cyclohydrolase 1, to the striatum in the brain, reprogramming transduced cells to secrete dopamine. [5] [6]